Results 81 to 90 of about 3,690 (206)

Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer‐related mortality among women worldwide. Triple‐negative breast cancer (TNBC) poses a major clinical challenge due to its aggressive nature, limited therapeutic options, and high propensity for drug resistance.
Lara Luzietti, Gustavo Salgado Pires, Ana Ryan, Crisamie Regidor, Matthew Hiller, Danilo Sarti, Tríona Ní Chonghaile, Pedro de Sena Murteira Pinheiro, Damir Varešlija, Daniel Alencar Rodrigues   +9 more
wiley   +1 more source

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

Molecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark, Achinto Saha, G. Lavender Hackman, Chelsea A. Friedman, Ruggiero Gorgoglione, Stefano Tiziani, John DiGiovanni   +6 more
wiley   +1 more source

Design and Synthesis of Polyamine‐Proteolysis Targeting Chimera Conjugates for Histone Deacetylase (HDAC) Degradation with Enhanced Cellular Uptake

ChemistryOpen, Volume 15, Issue 4, April 2026.
In this article, proteolysis targeting chimeras (PROTACs) bearing a polyamine linker capable of crossing cancer cell membranes via the polyamine transport system are synthesized and evaluated. The results provide valuable insights for the design of PROTACs with enhanced cellular uptake efficiency.
Yanran Liu, Wentian Chen, Yanwei Shang, Chaonan Tang, Xianming Zeng, Jun Li, Wenting Du   +6 more
wiley   +1 more source

Supplementary Figure 3 from Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling

, 2014
Supplementary Figure 3.
Naveena B. Janakiram (2206414), Michael Sadeghi (15095492), Rebekah L. Ritchie (15095486), Laura Biddick (14921567), Jagan Mohan R. Patlolla (15095489), Chinthalapally V. Rao (455812), Venkateshwar Madka (14924114), Stan Lightfoot (7114376), Misty Brewer (15094209), Vernon E. Steele (14895024), Altaf Mohammed (14905682)   +10 more
core   +1 more source

Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma [PDF]

, 2015
Neuroblastoma is a childhood tumor in which MYC oncogenes are commonly activated to drive tumor progression. Survival for children with high-risk neuroblastoma remains poor despite treatment that incorporates high-dose chemotherapy, stem cell support ...
Hogarty, Michael D, Bassiri, Hamid, Gilmour, Susan K, Norris, Murray D ; https://orcid.org/, Benavides, Adriana, Haber, Michelle ; https://orcid.org/   +5 more
core   +1 more source

Effets de la difluorométhylornithine après administration intraveineuse et son association avec de l'acéturate de diminazène contre Trypanosoma bruceichez des chiens infectés expérimentalement au Nigeria

Revue d’Elevage et de Médecine Vétérinaire des Pays Tropicaux, 1997
De la difluorométhylornithine (DFMO, eflornithine) a été donnée par voie intraveineuse (lV) à des chiens infectés expérimentalement par Trypanosoma brucei.
B.M. Anene, S.M. Anika, C.C. Chukwu
doaj   +1 more source

ODC1 Polyamine Metabolism Drives Prostate Cancer via AKT and Splicing

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Prostate cancer is an aggressive disease with limited quantifiable biomarkers. One gene of interest is ODC1, which encodes ornithine decarboxylase, the rate‐limiting enzyme converting ornithine to putrescine in polyamine metabolism. Although ODC1 is known to be involved in prostate cancer development, exactly how it drives the disease ...
Jian Ma, Ting Pan, Shengli Sun, Musitapa Mutalifu, Wei Yang, Yue Niu, Peng Chen   +6 more
wiley   +1 more source

Akt over-expression resists the effect of DFMO+diclofenac.

, 2013
Treatment of myr-flag-Akt overexpressing cells with DFMO and diclofenac resisted the changes in the levels of p-Akt ser-473 and cyclin D1 as compared to empty vector control and wild type A431 cells.
Zhiping Weng (51233), Mohammad Athar (156040), Farrukh Afaq (466811), Sandeep C. Chaudhary (481810), Craig A. Elmets (332860), Levy Kopelovich (32912), Aadithya Arumugam (481808), Sarang S. Talwelkar (481809)   +7 more
core   +1 more source

DFMO Reduces Cortical Infarct Volume after Middle Cerebral Artery Occlusion in the Rat

, 1993
Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, is induced in ischemic tissue and may mediate vasogenic edema and delayed neuronal death.
Cheryl A. Muszynski, Claudia S. Robertson, J. Clay Goodman, Charles M. Henley   +3 more
core   +1 more source

Sustained Delivery of Difluoromethylornithine (DFMO) by Means of Implantable Ceramic Devices

Journal of Investigative Surgery, 1988
A total of 25 Sprague-Dawley albino male rats were assigned to five groups, each group consisting of five rats. Polylactic acid-impregnated ALCAP capsules filled with 40 mg DFMO were implanted subcutaneously (sc) or intraperitoneally (ip) in group I and II rats, respectively.
H A, Benghuzzi, P K, Bajpai
openaire   +2 more sources